Suchergebnisse - "Stilgenbauer, Stephan"

PubPharm (32)

1

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

enthalten in: Blood advances | 2024

von Stilgenbauer, S. | Tausch, E. | Roberts, A. | +19

2

Final analysis of the CLL2-GIVe trial : obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut

enthalten in: Blood | 2023

von Huber, H. | Tausch, E. | Schneider, C. | +22

CommentIn: Blood. 2023 Sep 14;142(11):941-943. - PMID 37707873

3

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

enthalten in: Blood | 2023

von Fürstenau, M. | Thus, Y. | Robrecht, S. | +44

CommentIn: Blood. 2023 Aug 3;142(5):402-404. - PMID 37535371

4

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

enthalten in: The New England journal of medicine | 2023

von Eichhorst, B. | Niemann, C. | Kater, A. | +148

CommentIn: Nat Rev Clin Oncol. 2023 Aug;20(8):503. - PMID 37237098

5

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

enthalten in: Nature communications | 2023

von Al-Sawaf, O. | Zhang, C. | Jin, H. | +20

ErratumIn: Nat Commun. 2023 Oct 23;14(1):6724. - PMID 37872229

6

Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older

enthalten in: Leukemia & lymphoma | 2022

von Simon, F. | Giza, A. | Robrecht, S. | +13

7

Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG) : a multicentre, open-label, phase 2 trial

enthalten in: The Lancet. Haematology | 2022

von Cramer, P. | Fürstenau, M. | Robrecht, S. | +19

CommentIn: Lancet Haematol. 2022 Oct;9(10):e711-e712. - PMID 35988548

8

Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Fürstenau, M. | Weiss, J. | Giza, A. | +13

9

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

enthalten in: Blood | 2022

von Huber, H. | Edenhofer, S. | von Tresckow, J. | +20

CommentIn: Blood. 2022 Mar 3;139(9):1264-1265. - PMID 35238892

10

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy

enthalten in: American journal of hematology | 2022

von Popovic, R. | Dunbar, F. | Lu, C. | +14